Last reviewed · How we verify

Ethyl alcohol — Competitive Intelligence Brief

Ethyl alcohol (Ethyl alcohol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytotoxic agent / Sclerosing agent. Area: Oncology.

marketed Cytotoxic agent / Sclerosing agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ethyl alcohol (Ethyl alcohol) — South Egypt Cancer Institute. Ethyl alcohol acts as a protoplasmic poison and denaturant that kills cancer cells through protein denaturation and cellular damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ethyl alcohol TARGET Ethyl alcohol South Egypt Cancer Institute marketed Cytotoxic agent / Sclerosing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytotoxic agent / Sclerosing agent class)

  1. South Egypt Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ethyl alcohol — Competitive Intelligence Brief. https://druglandscape.com/ci/ethyl-alcohol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: